Physician profile
Jihad Jaffer
NPI 1366659294
$2,243.21
in general payments reported to CMS, 2019-2025
13 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what 88% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $11.34 · 2022: $13.55 · 2023: $808 · 2024: $121 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,633 · Food and Beverage: $339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,632.65 |
| Food and Beverage | $338.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $1,784.06 | 2023-2025 | Iovera |
| Merz North America, INC. | $140.54 | 2019 | |
| Lifeward, INC. | $79.07 | 2024 | |
| Merz Pharmaceuticals, LLC | $47.02 | 2023 | Xeomin |
| Microtransponder, INC. | $41.83 | 2022-2025 | |
| Hollister Incorporated | $33.05 | 2023 | Vapro Plus Pocket |
| Novartis Pharmaceuticals Corporation | $24.58 | 2019-2020 | |
| Emd Serono, INC. | $20.93 | 2019 | |
| Medtronic USA, INC. | $16.83 | 2019 | |
| Greenwich Biosciences, INC. | $16.12 | 2019 | |
| Csl Behring | $15.75 | 2019 | |
| Promius Pharma LLC | $12.57 | 2019 | |
| Amneal Pharmaceuticals LLC | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jihad Jaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.